Cardiomyopathy Trial, Recruiting (NCT06474819)

Cardiomyopathy Trial, Recruiting NCT06474819 Sponsor: Institut d'Investigació Biomèdica de Bellvitge Condition: Cardiomyopathy

Printed from Voxsanity (voxsanity.com.au) — NCT06474819 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Cardiomyopathy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are receiving your first ever pacemaker (either a single- or dual-chamber device) because your heart beats too slowly due to a serious electrical conduction problem between the upper and lower chambers of the heart, or because you have an irregular heart rhythm (atrial fibrillation) causing your heart to beat dangerously slowly (fewer than 45 beats per minute).
Your heart's pumping strength, measured by an ultrasound scan done within 7 days before your pacemaker is fitted, must be above 50% (this is considered a normal or near-normal pumping function).
You are willing and able to sign a consent form agreeing to take part in the trial.

Who may not be able to join:

You are not expected to live for more than 12 months due to any serious illness.
You have a severe problem with one or more of your heart valves that needs to be treated or repaired.
You have had unstable chest pain, a heart attack, a procedure to unblock heart arteries, or heart valve surgery or a valve procedure in the 90 days before your pacemaker is fitted.
You are already taking part in another clinical trial that could affect the results of this study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Andrea Di Marco, MD, PhD, IDIBELL and Hospital Universitario de Bellvitge

Phone: +34932 60 75 00

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06474819

Sponsor: Institut d'Investigació Biomèdica de Bellvitge

Phase: Not Applicable

Status: Recruiting

Condition: Cardiomyopathy

Trial contact: +34932 60 75 00

More information: https://clinicaltrials.gov/study/NCT06474819

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are receiving your first ever pacemaker (either a single- or dual-chamber device) because your heart beats too slowly due to a serious electrical conduction problem between the upper and lower chambers of the heart, or because you have an irregular heart rhythm (atrial fibrillation) causing your heart to beat dangerously slowly (fewer than 45 beats per minute).
Your heart's pumping strength, measured by an ultrasound scan done within 7 days before your pacemaker is fitted, must be above 50% (this is considered a normal or near-normal pumping function).
You are willing and able to sign a consent form agreeing to take part in the trial.

Who may not be able to join:

You are not expected to live for more than 12 months due to any serious illness.
You have a severe problem with one or more of your heart valves that needs to be treated or repaired.
You have had unstable chest pain, a heart attack, a procedure to unblock heart arteries, or heart valve surgery or a valve procedure in the 90 days before your pacemaker is fitted.
You are already taking part in another clinical trial that could affect the results of this study.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Institut d'Investigació Biomèdica de Bellvitge

Registry

ClinicalTrials.gov

Start date

12 July 2024

Est. completion

12 January 2027

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

Pacing-induced cardiomyopathy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov